PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 

NuvOx Pharma

Press Releases

Click on the press release below to view it in its entirety

Receive press releases from NuvOx Pharma: By Email RSS Feeds:
Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx has received a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to fund the development of a new strategy to detect pancreatic cancer. The grant, 2R44CA203090-02, entitled “Thy-1... - July 14, 2018
NuvOx Pharma, a clinical stage biotechnology company, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that may... - December 30, 2017
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $317,743 for a study in pigs for NuvOx Pharma's drug, NVX-308, in heart attack. - April 14, 2017
NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. have signed a licensing agreement for the exclusive development and sales of NVX-408 for China for treating hemorrhagic shock and perioperative blood loss. NVX-408 is an oxygen therapeutic that is injected intravenously, flows through the lungs... - January 26, 2017
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, “B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant,... - November 03, 2016
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, “Fibrin Targeted Microbubbles and Ultrasound for Treatment... - August 27, 2016
Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients. The trial will be performed at the University of Arkansas Medical System in Little... - August 22, 2016
Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer (STTR)... - May 28, 2016
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle... - February 14, 2016
The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically involves... - February 13, 2016
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-108 for treatment of Glioblastoma. Orphan status provides NuvOx with development and commercial incentives such as tax credits for qualified clinical testing and market exclusivity for 7 years after the marketing approval is granted. - December 07, 2015
Press Releases 1 - 11 of 11 Page: 1
Promote Your Business